Guardant Health, Inc. ( GH) $ 38.52
2.03 (5.01 %)
| Symbol | GH |
| Price | $38.52 |
| Beta | 0.689 |
| Volume Avg. | $1.38 M |
| Market Cap | $3.93 B |
| 52 Week Range | $27.65 - $133.82 |
Guardant Health, Inc. opened the day at $38.52 which is +'5.01 % on yesterday's close. Guardant Health, Inc. has a 52 week high of $133.82 and 52 week low of $27.65, which is a difference of $106.17. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $3.93 B and total net profit is $373653000 which means the company is trading at 10.51 times profit to market capitalization. Theoretically, if you were to buy Guardant Health, Inc. for $3.93 B, it would take 15 years to get your money back. Guardant Health, Inc. are in the Diagnostics & Research space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Guardant Health, Inc. Stock Forecast - Is Guardant Health, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Neutral | |
| DE Score | Strong Buy | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -9.358 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -1.072 |
Valuing Guardant Health, Inc.
| Price Book Value Ratio | 7.360 | Price To Book Ratio | 7.360 |
| Price To Sales Ratio | 10.032 | Price Earnings Ratio | -9.358 |
How liquid is Guardant Health, Inc.
| Current Ratio | 4.866 |
| Quick Ratio | 4.574 |
Debt
| Debt Ratio | 0.750 | Debt Equity Ratio | 2.995 |
| Long Term Debt To Capitalization | 0.719 | Total Debt To Capitalization | 0.721 |
Latest news about Guardant Health, Inc.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. William Blair 42nd Annual Growth Stock Conference in Chicago, IL Presentation on Tuesday, June 7th at 11:20 a.m. Central Time Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA Fireside Chat on Tuesday, June 14 th at 9:20 a.m. Pacific Time Interested parties may acc
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Among the 19 abstracts are oral presentations highlighting the use of real-world data to identify resistance to early treatment in advanced breast cancer and the use of enhanced biomarker analysis to evaluate progression-free survival data in metasta
Investors reacted negatively after the company's Q1 update.
Guardant Health Inc's (NASDAQ: GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology testing revenues grew 32% to $84.1 million, driven by the increase in clinical and biopharma testing.
Guardant Health, Inc. (NASDAQ:GH ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Alex Kleban - VP, IR Helmy Eltoukhy - Co-CEO AmirAli Talasaz - Co- CEO Mike Bell - CFO Conference Call Participants Puneet Souda - SVB Securities Dan Arias - Stifel Jack Meehan - Nephron Research Yih-Ming Tu - Morgan Stanley Derik De Bruin - Bank of America Kyle Mikson - Canaccord Mark Massaro - BTIG Max Masucci - Cowen Patrick Donnelly - Citi Julie Qin - JPMorgan David Delahunt - Goldman Sachs Brian Weinstein - William Blair Operator Hello everyone. And welcome to the Guardant Health First Quarter Of 2022 Financial Results Call.
About Guardant Health, Inc.
Description :
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
